Effect of content and format of prescription drug labels on readability, understanding, and medication use: a systematic review.

Full Abstract

OBJECTIVE:
To evaluate the evidence regarding the optimal content and format of prescription labels that might improve readability, understanding, and medication use.

DATA SOURCES:
We performed a systematic review of randomized controlled trials, observational studies, and systematic reviews from MEDLINE and the Cochrane Database (1990-June 2005), supplemented by reference mining and reference lists from a technical expert panel.

STUDY SELECTION:
We selected studies that focused on the content of physician-patient communication about medications and the content and format of prescription drug labels.

DATA EXTRACTION:
Two reviewers extracted and synthesized information about study design, populations, and outcomes.

DATA SYNTHESIS:
Of 2009 articles screened, 36 that addressed the content of physician-patient communication about medications and 69 that were related to the content or format of medication labels met review criteria. Findings showed that patients request information about a drug's indication, expected benefits, duration of therapy, and a thorough list of potential adverse effects. The evidence about label format supports the use of larger fonts, lists, headers, and white space, using simple language and logical organization to improve readability and comprehension. Evidence was not sufficient to support the use of pictographic icons. Little evidence linked label design or content to measurable health outcomes, adherence, or safety.

CONCLUSIONS:
Evidence suggests that specific content and format of prescription drug labels facilitate communication with and comprehension by patients. Efforts to improve the labels should be guided by such evidence, although additional study assessing the influence of label design on medication-taking behavior and health outcomes is needed. Several policy options exist to require minimal standards to optimize medical therapy, particularly in light of the new Medicare prescription drug benefit.

Learn Faster Today Improve your study skills

Author information

Author/s: Shrank, William (W); Avorn, Jerry (J); Rolon, Cony (C); Shekelle, Paul (P);

Affiliation: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. wshrank(-atsign-)partners.org

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

Journal: The Annals of pharmacotherapy (Ann Pharmacother), published in United States. (Language: eng)

Reference: 2007-May; vol 41 (issue 5) : pp 783-801

Dates: Created 2007/05/02; Completed 2007/05/24; Revised 2007/11/15;

PMID: 17426075, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

These are the highest related articles currently in the database:

See 100+ related articles.